Thrombocytopenia in critically ill patients receiving thromboprophylaxis: Frequency, risk factors, and outcomes

Chest

Volumn 144, Issue 4, 2013, Pages 1207-1215

  Williamson, David R ^a,b   Albert, Martin ^a,c   Heels Ansdell, Diane ⁱ   Arnold, Donald M ^d,i   Lauzier, François ^e   Zarychanski, Ryan ^g   Crowther, Mark ^q   Warkentin, Theodore E ⁱ   Dodek, Peter ^h   Cade, John ^o   Lesur, Olivier ^f   Lim, Wendy ⁱ   Fowler, Robert ^j   Lamontagne, Francois ^f   Langevin, Stephan ^e   Freitag, Andreas ⁱ   Muscedere, John ⁿ   Friedrich, Jan O ^j,k,l   Geerts, William ^j,k   Burry, Lisa ^m   Alhashemi, Jamal ^p   Cook, Deborah ⁱ   more..

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b Departments of Pharmacy   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d CANADIAN BLOOD SERVICES   (Canada)

^e University Laval   (Canada)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^l ST MICHAEL'S HOSPITAL   (Canada)

^m MOUNT SINAI HOSPITAL   (Canada)

ⁿ QUEEN S UNIVERSITY   (Canada)

^o ROYAL MELBOURNE HOSPITAL   (Australia)

^p KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^q NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HYPERTENSIVE FACTOR; INOTROPIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTICOAGULATION; APACHE; ARTICLE; BLEEDING; BLOOD TRANSFUSION; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DEATH; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; RISK FACTOR; SEPSIS; SINGLE BLIND PROCEDURE; SURGICAL PATIENT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 84885116785     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0121     Document Type: Article

References (31)

1. Chakraverty R, Davidson S, Peggs K, Stross P, Garrard C, Littlewood TJ. The incidence and cause of coagulopathies in an intensive care population. Br J Haematol. 1996; 93 (2): 460-463.
2. Shalansky SJ, Verma AK, Levine M, Spinelli JJ, Dodek PM. Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy. 2002; 22 (7): 803-813.
3. Akca S, Haji-Michael P, de Mendonça A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med. 2002; 30 (4): 753-756.
4. Crowther MA, Cook DJ, Meade MO, et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care. 2005; 20 (4): 348-353.
5. Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000; 28 (6): 1871-1876.
6. Vandijck DM, Blot SI, De Waele JJ, Hoste EA, Vandewoude KH, Decruyenaere JM. Thrombocytopenia and outcome in critically ill patients with bloodstream infection. Heart Lung. 2010; 39 (1): 21-26.
7. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med. 2002; 30 (8): 1765-1771.
8. Wang HL, Aguilera C, Knopf KB, Chen TM, Maslove DM, Kuschner WG. Thrombocytopenia in the intensive care unit [published online ahead of print January 9, 2012]. J Intensive Care Med. doi: 10.1177/0885066611431551.
9. Cook D, Meade M, Guyatt G, et al; PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011; 364 (14): 1305-1314.
10. Crowther MA, Cook DJ, Albert M, et al; Canadian Critical Care Trials Group. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care. 2010; 25 (2): 287-293.
11. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000; 342 (24): 1773-1777.
12. Ecker RD, Wijdicks EF, Wix K, McClelland R. Does famotidine induce thrombocytopenia in neurosurgical patients? J Neurosurg Anesthesiol. 2004; 16 (4): 291-293.
13. Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest. 2011; 139(2): 271-278.
14. Greinacher A, Selleng K. Thrombocytopenia in the intensive care unit patient. Hematology Am Soc Hematol Educ Program. 2010: 135-143.
15. Arnold DM, Crowther MA, Cook RJ, et al. Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses. Transfusion. 2006; 46 (8): 1286-1291.
16. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med. 2007; 35 (4): 1165-1176.
17. Moreau D, Timsit JF, Vesin A, et al. Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays. Chest. 2007; 131 (6): 1735-1741.
18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13 (10): 818-829.
19. Arnold DM, Donahoe L, Clarke FJ, et al. Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med. 2007; 30 (2): E93-E102.
20. Arnold DM, Lauzier M, Rabbat C, et al. Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illness. Thromb Res. 2013 ;131(3): 204-209.
21. Masrouki S, Mebazaa MS, Mestiri T, Ben Ammar MS. Risk factors of mortality in critically ill patients with thrombocytopenia [in French]. Ann Fr Anesth Reanim. 2004; 23(8): 783-787.
22. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998; 35(4)(suppl 5): 9-16.
23. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005; 106 (8): 2710-2715.
24. Nikolsky E, Sadeghi HM, Effron MB, et al. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol. 2005; 96 (4): 474-481.
25. Ben Hamida C, Lauzet JY, Rézaiguia-Delclaux S, et al. Effect of severe thrombocytopenia on patient outcome after liver transplantation. Intensive Care Med. 2003; 29 (5): 756-762.
26. Hanes SD, Quarles DA, Boucher BA. Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother. 1997; 31 (3): 285-289.
27. Stéphan F, H ollande J, R ichard O, C heffiA, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU. Chest. 1999; 115 (5): 1363-1370.
28. Baughman RP, Lower EE, Flessa HC, Tollerud DJ. Thrombo cytopenia in the intensive care unit. Chest. 1993; 104 (4): 1243-1247.
29. Stephan F, Montblanc Jd, CheffiA, Bonnet F. Thrombocytopenia in critically ill surgical patients: a case-control study evaluating attributable mortality and transfusion requirements. Crit Care. 1999; 3 (6): 151-158.
30. Brogly N, Devos P, Boussekey N, Georges H, Chiche A, Leroy O. Impact of thrombocytopenia on outcome of patients admitted to ICU for severe community-acquired pneumonia. J Infect. 2007; 55 (2): 136-140.
31. Lauzier F, Arnold D, Rabbat C, et al. In medical-surgical ICU patients, major bleeding is common but independent of heparin prophylaxis. Crit Care. 2012; 16 (suppl 1): 435.